EMGLIF LMXR 25/5/1000MG TAB

EMGLIF LMXR is a triple-action diabetes management tablet combining empagliflozin, linagliptin, and metformin HCl. This fixed-dose combination works synergistically to help regulate blood sugar levels through multiple mechanisms: empagliflozin promotes glucose excretion, linagliptin inhibits DPP-4 enzyme, and metformin reduces hepatic glucose production. Designed for patients with type 2 diabetes who require comprehensive glycemic control, EMGLIF LMXR offers convenient once-daily dosing to improve treatment adherence and metabolic outcomes.